CONFERENCE DAY ONE
SEPTEMBER 9, 2025
PART ONE: FIND YOUR FUTURE PARTNER
Bringing you a targeted and scientifically aligned partnership opportunity from the start, this opening section brings key buyers
together in a unique and unmissable format to find your next partner and route to more capital.
8.00-8:45: Insights into pharma’s outlook for ADC deal-making with the pharma icebreaker panel
9.00-10.30: Introductions & Protected Networking: Qualify connections, hear feedback and generate interest for follow-up meetings at the pharma icebreaker roundtables
11.15-12.15: Where will Investors Invest? Understand what will drive or inhibit investor interest in ADC technologies
12.15-12.45: Connect with Investors: Swap business cards and find your company’s fit with investors during the investor icebreaker speed networking
7:50 am Session Chair’s Opening Remarks
Strategic Priorities & Opinions on New Innovations for Future Partnerships in ADC
8:00 am Pharma Icebreaker: Moderated Discussion Revealing Insights into Pharma’s Wish List & Successful Deal Structure
8:45 am Short Comfort Break Ahead of Networking Session
For Business Development & Networking: Follow up with Pharma
9:00 am Unlocking Unmatched Meetings:
Synopsis
- The Icebreaker Tables guarantee face-time for biotech to sit at tables with pharma from the panel before.
- Once meetings schedules form on the One-on-One Partnering Portal, pharma pick biotech of interest and biotech select pharma not yet on their meeting calendar. From this, we create a schedule for biotech to rotate through match-making tables. Break the ice, ask questions to assess alignment and initiate interest for follow up with key contacts who are on your hit-list but not yet on your One-on-One Partnering schedule.
For Scientific Insights & Discussion: Assessing Future Research Trends
9:00 am Considerations for Quality of Life When Assessing Assets Earlier in Development
9:30 am ADCs x Radioligands: The Use of One Technology to Advance the Other
Synopsis
- Discussing key learnings for both technologies to understand where they can lend value to each other
- Convergence of targeting technologies between ADCs and Radio
- Using linker technology from ADC to improve the rapid uptake and excretion profile of radioligands when separating target ligands from radioligand payloads in the tumor
- Overcoming challenges associated with elimination, how do you get an ADC out of the body?
10:00 am Breaking Down the ADC Boom
Synopsis
- Analyzing the ADC landscape expansion, focusing on emerging trends from recent activity
- Discussing novel approaches where most use is seen, and looking into dual payloads, bispecific ADCs, degrader ADCs and more
- What were the key highlights and updates for ADC development across 2025?
10:30 am Morning Break & One-on-One Meeting Schedule Opens
11:45 am Investor Icebreaker: When Being Selective, where will Investors Invest?
Synopsis
- For both venture and investing out of public funds, what will drive investment in ADCs and what will inhibit it?
- With the data readouts from ASCO, will your considerations for investment change?
- How can and will ADCs remain relevant to investors?
12:15 pm Investors Icebreaker: Speed Networking
Synopsis
Straight after the Investor Icebreaker, join high tables in small groups with an investor at each table. For rounds of five minutes, biotech stays at tables and investors move around. Rapidly gauge alignment between portfolios and stage of the company, share business cards, or ask a follow-up question from the panel before the investors rotate and a new
round begins.
12:45 pm Lunch Break & Networking
3:00 pm One-on-One Meeting Schedule Pauses for Presentations to Start
PART TWO: SHOWCASE YOUR SCIENCE
Designed to foster excitement and engagement in innovative companies, be part of back-to-back presentations to showcase
your pipeline, platform, and technologies to a room of aligned and qualified decision-makers.
Novel Payloads & Linker Conjugation
Synopsis
Demonstrating Value versus Risk, to Diversify & Invest in Novel Payload & Advanced Linker Conjugation Technologies
3:10 pm Session Chair’s Opening Remarks
Synopsis
- Novel Payloads as the New Value Driver for ADCs
- Why are new payloads needed?
- What new payloads are on the horizon?
- Case Study: Focusing on Iksuda’s novel protein alkylator (ProAlk) payload
3:30 pm Fully-Integrated Innovation Engine Delivering a New Generation of ADCs & Antibody Cancer Therapeutics
Synopsis
- Demonstrating clinical stage, wholly owned, lead assets against validated cancer targets, and promising preclinical pipeline
- Discussing novel drug development platform based on multiple, seamlessly integrated, proprietary technologies
- Showcasing fully integrated, in-house drug discovery, development & manufacturing
3:50 pm Novel & Dual Payloads: Assessing Linker Conjugation Technologies That Encourage Flexibility in Payloads
Synopsis
- Evaluating the right ratios, the advantages of releasing drugs in specific ratios, and which combination of drugs make sense when considering dual payloads
- Discussing the parameters of small molecule degraders and how that lends them to make good payloads
- Advancing cytoxic or immune-stimulating payloads with novel MoAs
Afternoon Drinks Reception & Networking
4.00: ““People work with people”. Enjoy an informal networking drinks reception with all attending colleagues to catch up, candidly network, initiate and nurture business relationships built before or during the conference so far.
4.00 - 6.00: One-on-One Meeting Schedule Re-Opens
Available from 4.00 to 6.00 make the most of catching contacts away from the office and capitalize on meeting space adjacent to the networking drinks reception.